Regulatory Role of N6-methyladenosine (m\textsuperscript{6}A) Modification in Osteosarcoma

Yujie Zhang\textsuperscript{1†}, Yanyan Wang\textsuperscript{2†}, Liwei Ying\textsuperscript{1†}, Sifeng Tao\textsuperscript{2}, Mingmin Shi\textsuperscript{1}, Peng Lin\textsuperscript{1}, Yangxin Wang\textsuperscript{1} and Bin Han\textsuperscript{1}

\textsuperscript{1} Department of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, \textsuperscript{2} Department of Oncology Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

Osteosarcoma is the most common primary bone malignancy, typically occurring in childhood or adolescence. Unfortunately, the clinical outcomes of patients with osteosarcoma are usually poor because of the aggressive nature of this disease and few treatment advances in the past four decades. N6-methyladenosine (m\textsuperscript{6}A) is one of the most extensive forms of RNA modification in eukaryotes found both in coding and non-coding RNAs. Accumulating evidence suggests that m\textsuperscript{6}A-related factors are dysregulated in multiple osteosarcoma processes. In this review, we highlight m\textsuperscript{6}A modification implicated in osteosarcoma, describing its pathophysiological role and molecular mechanism, as well as future research trends and potential clinical application in osteosarcoma.

Keywords: N6-methyladenosine (m\textsuperscript{6}A), molecular mechanisms, osteosarcoma, biomarker, therapeutic target

INTRODUCTION

Osteosarcoma is a relatively rare bone malignancy that predominantly occurs in children and adolescents (1, 2). It is highly aggressive and difficult-to-treat (3, 4). Although the introduction of chemotherapy since the 1970s has increased the 5-year survival rate of patients with non-metastatic osteosarcoma to 70%, the 5-year survival rate of patients with metastatic osteosarcoma is only 20% (5, 6). More importantly, metastasis of osteosarcoma is not uncommon (7). Osteosarcoma is known to exhibit high heterogeneity and significant genome complexity (8–10); thus, tremendous efforts are needed to define the biology of osteosarcoma for developing new therapeutic alternatives.

The discovery of heritable alterations of chromatin structure and DNA modifications that do not change their DNA or RNA sequence itself paves a new field of epigenetics (11, 12). N6-methyladenosine (m\textsuperscript{6}A) modification refers to the addition or deletion of the methyl group to/from the nitrogen on the 6th carbon of the adenine nucleotide, which is one of the most abundant epigenetic modifications found in RNA molecules (13). First discovered by Desrosiers in the 1970s, m\textsuperscript{6}A modification has been found to be involved in almost all steps of RNA processing and metabolism, including pre-mRNA splicing, export, translation, stabilization, and degradation (14–19). With the burgeoning advances in molecular biology and sequencing, m\textsuperscript{6}A modification has been reported to be implicated in virtually all cellular functions and multiple diseases (including osteosarcoma) (20–23). In this review, we intended to summarize the current advances in the
pathophysiological roles and molecular mechanism of m^6^A modification in osteosarcoma and related diseases, and discuss the potential clinical application of m^6^A modification in osteosarcoma.

**m^6^A REGULATION**

Similar to DNA and histone methylation, m^6^A modification is a dynamic and reversible process that is regulated by methylases and demethylases (Figure 1) (24, 25).

M^6^A methylases, also called “writers”, can transfer a methyl group to the N-6 position of adenosine in the nucleic acid (26). It commonly works in the form of a multicomponent m^6^A methyltransferase complex (MTC) (27). Methyltransferase-like 3 (METTL3) has long been considered as the central catalytic subunit of MTC, while other components have recently been discovered (28). METTL14 is an allosteric adaptor of METTL3 that can stabilize METTL3 and recognize the substrate (29). In addition, Wilms tumor 1-associated protein (WTAP), Vir-like m^6^A methyltransferase associated (KIAA1429), and Cbl proto-oncogene-like 1 (Hakai) participate in the formation of MTC and play a vital role in m^6^A modification (30–32).

M^6^A demethylases, also named “erasers”, are proteins that remove the methyl groups from RNA; thus, conferring a reversible and dynamic nature to the regulation of m^6^A methylation (33). These enzymes mainly include fat mass and obesity-associated protein (FTO), and α-ketoglutarate-dependent dioxygenase alk B homolog 5 (ALKBH5) (34, 35). FTO was the first identified m^6^A demethylase (36). Since then, research on m^6^A demethylation has gained attention. FTO can demethylate m^6^A into N6-hydroxymethyladenosine (hm^6^A), which is further converted to N6-formyladenosine (f^6^A) before being hydrolyzed to the stable form adenine (37). The writers and erasers maintain the dynamic balance of m^6^A in the transcriptome, which is essential for normal physiological processes.

In addition to writers and erasers, “readers” are binding proteins that recognize the chemical signatures that are important for the regulation of m^6^A modification (38). The YTH domain-containing proteins are the first discovered readers, which interact with m^6^A through a “tryptophan cage” (39). The family of YTH domain-containing proteins consist of the following five proteins: YTHDC1, YTHDC2, YTHDF1, YTHDF2, and YTHDF3 (40). M^6^A can alter the structure of RNA substrates, and thereby, promote the binding of RNA-binding proteins (RBPs) to substrates (41). These RBPs are called “m^6^A structural switch” readers, and include heterogeneous nuclear ribonucleoprotein C (hnRNPC), hnRNPG, and hnRNPA2B1 (25, 41, 42). Insulin-like growth factor 2 mRNA-binding (IGF2BP) proteins (IGF2BP1, IGF2BP2, and IGF2BP3) are another category of m^6^A readers, which can stabilize RNA by interacting with YTHDF proteins or in an m^6^A structural switch manner (43, 44).

M^6^A can affect the whole process of gene expression, including transcription, post-transcription, translation, and post-translation (45). In the “life cycle” of m^6^A mRNA (Figure 2) (46, 47), the m^6^A writers and erasers first regulate the change in m^6^A during transcription in the nucleus. Then, m^6^A binds to specific nuclear readers and affect mRNA splicing, exporting, and other bioprocesses (48, 49). After being exported to the cytoplasm, the cytoplasm readers bind to m^6^A and influence mRNA decay, translation, and stabilization (46, 50). Through these processes, m^6^A modification regulates gene expression and exerts profound

![FIGURE 1](image-url) | The molecular mechanism of m^6^A modification. It is a dynamic and reversible epigenetic modification that is regulated by “writers” and “erasers.” m^6^A markers in the RNA can be recognized by “readers.”
and diverse functions in cell differentiation, immune response, and disease development, especially tumorigenesis, progression, and cancer metastasis (51–54).

**m6A AND BONE DEVELOPMENT**

The bone is a complex connective tissue, which is always under a dynamic balance between bone formation mediated by osteoblasts and bone resorption regulated by osteoclasts (55). If the bone homeostasis is disturbed, many bone metabolic diseases such as osteosarcoma, osteoporosis, and osteoarthritis may occur (56). M6A is reported to participate in the regulation of bone homeostasis (57). METTL3 is significantly increased during the process of osteogenic differentiation of the bone marrow stem cells (BMSCs). Specifically, silencing METTL3 can suppress the osteogenic differentiation by directly and indirectly regulating RUNX2 (METTL3/m6A-pre-miR-320/miR-320-RUNX2 Axis) in BMSCs (58). Remarkably, the expression of METTL3 was also increased during osteoclast differentiation. It can regulate the bone resorption by controlling Atp6v0d2 mRNA degradation and Traf6 mRNA nuclear export (59). METTL14 was found to be positively associated with bone formation in older women with fractures and ovariectomized mice. It promotes osteoblast activity by regulating miR-103-3p processing via microprocessor protein DGCR8 (60). Similarly, the FTO, represented as the RNA demethylase, is also closely related to the fate of BMSCs. Li et al. (61) reported that FTO could interact with miR-149-3p and promote osteogenic differentiation of BMSCs.

**m6A AND OSTEOSARCOMA**

Osteosarcoma always occurs where the bones are growing the fastest (62). The inseparable relationship between m6A regulators and bone development implies that m6A modification might contribute to the progression of osteosarcoma. Herein, we comprehensively review the current research on the association of m6A and osteosarcoma.

**Dysregulation of m6A Writers in Osteosarcoma**

In osteosarcoma cells, m6A writers, including METTL3, METTL14, WTAP, and KIAA1429 are mostly present in the nucleus (63). Zhou et al. (64) revealed that METTL3 acts as an oncogene in osteosarcoma. Knockdown of METTL3 can suppress the proliferation, migration, and invasion of the human osteosarcoma cell lines SAOS-2 and MG63 by inhibiting the m6A methylation level and expression of the ATPase family AAA domain-containing protein 2 (ATAD2). Additionally, Miao et al. (65) found that METTL3 expression and m6A methylation levels were higher in human osteosarcoma tissues and osteosarcoma cells. METTL3 can promote osteosarcoma development by directly increasing the m6A methylation level and the expression of lymphoid enhancer-binding factor 1(LEF1), and by activating the Wnt/β-catenin signaling pathway. METTL3 has also been found to facilitate the methylation of GTP-binding protein (DRG) 1, and thereby, promoting osteosarcoma growth, migration, and colony formation (66). Conversely, METTL14 has an inhibitory effect in osteosarcoma. METTL14 overexpression promotes osteosarcoma cell apoptosis and slows tumor progression through caspase 3 activation (67). Recently, Chen et al. (68) demonstrated that another m6A writer, WTAP, can positively regulate osteosarcoma tumorigenesis and metastasis by reducing the stability of HMBOX1 in a m6A-dependent manner. Inhibiting PI3K/AKT pathways can partly reverse WTAP/ HMBOX1- induced osteosarcoma progression.
METTL3/14 also plays an important role in modulating the chemoresistance of osteosarcoma. METTL3 and METTL14 decrease the RNA level of tripartite motif 7 (TRIM7), while the upregulation of TRIM7 can increase metastasis and the chemoresistance of osteosarcoma by regulating ubiquitination of breast cancer metastasis suppressor 1 (BRMS1) (69). The transcriptome-wide m⁶A sequencing result of chemoresistant osteosarcoma stem cells revealed that over-expression of METTL3 and low METTL14 expression are associated with doxorubicin chemoresistance and stemness of osteosarcoma cells (70). The regulatory mechanism of writer is shown in Table 1 and Figure 3.

Dysregulation of m⁶A Erasers in Osteosarcoma

The m⁶A erasers, FTO and ALKBH5, are distributed in both the nucleus and cytoplasm (63). The effect of ALKBH5 in osteosarcoma remains controversial. Chen et al. (71) revealed that ALKBH5 can promote osteosarcoma cell proliferation and tumor growth by decreasing the m⁶A modification of plasmacytoma variant translocation 1 (PVT1), subsequently impairing the binding of reader protein YTHDF2 in PVT1. However, Yuan et al. (72) showed that ALKBH5 can epigenetically silence pre-miR-181b-1/YAP signaling axis, and thus, suppress tumor progression in osteosarcoma. In addition, upregulation of ALKBH5 expression also contributes to chemoresistance and predicts worse metastasis-free survival in patients with osteosarcoma (70). The regulatory mechanism is shown in Table 1 and Figure 3.

Dysregulation of m⁶A Readers in Osteosarcoma

The subcellular location of m⁶A readers in osteosarcoma cells is relatively complicated. YTHDF1 and YTHDF2 are mainly distributed in the cytoplasm. YTHDC1 is mainly located in the nucleus, while YTHDC2 is uniformly distributed in the nucleus and cytoplasm. Additionally, HNRNPC and HNRNPA2B1 are found only in the nucleus (63). YTHDF2 can directly bind to the 3′-UTR of TRIM7 mRNA and negatively regulate the expression of TRIM7 in osteosarcoma HOS and MG63 cells (69). ELAVL1 (also known as HuR) is a recently discovered m⁶A reader, which is located in the nucleus. It has been reported to regulate the stability of DRG1 mRNA. Silencing ELAVL1 inhibits osteosarcoma progression by

| m⁶A regulators | Role in cancer | Biological function | Target/signaling axis | Ref. |
|----------------|---------------|---------------------|----------------------|-----|
| METTL3         | Oncogene      | Promote cell proliferation, migration, and invasion | ATAD2                | (64) |
|                | Tumor suppressor | Suppress osteosarcoma metastasis and chemoresistance | TRIM7/BRMS1           | (69) |
| METTL14        | Tumor suppressor | Promotes osteosarcoma cell apoptosis and slows tumor progression | Caspase 3             | (67) |
| WTAP           | Oncogene      | Promote proliferation and metastasis | HMBOX1/PI3K/AKT       | (68) |
| ALKBH5         | Oncogene      | Promote cell proliferation, tumor growth | PVT1                 | (71) |
| YTHDF2         | Oncogene      | Suppress cell proliferation, tumor growth | Critical for ALKBH5-mediated PVT1 stability | (71) |
| hnrNPA2/B1     | Oncogene      | Suppress osteosarcoma metastasis and chemoresistance | Directly bind to the 3′-UTR of TRIM7 mRNA | (69) |
| ELAVL1         | Oncogene      | Independent prognostic factor for overall survival | DRG1                 | (63) |

FIGURE 3 | The pathophysiological roles and molecular mechanism of m⁶A modification in osteosarcoma.
decreasing the expression of DRG1 in an m6A-dependent pattern (66). These processes have been summarized in Table 1 and Figure 3.

### m6A AND OSTEOSARCOMA-RELATED DISEASES

#### m6A and Bone Disease

As an essential component of epigenetic regulation, m6A modification also has an inextricable link with other bone diseases, such as intervertebral disc degeneration (IDD), osteoarthritis, and osteoporosis (73). In IDD, the microarray results showed that most of the dysregulated RNA was in a demethylated state. FTO and ZFP217 can demethylate LOC102555094 and activate downstream Wnt pathway, which may contribute to metabolic reprogramming of glucose metabolism in the IDD process (74). METTL14 can accelerate TNF-α-induced nucleus pulposus cell cycle arrest and senescence via processing miR-34a-5p (75). In osteoarthritis, METTL3 is suggested to be responsible for the development of the disease by regulating NF-kB signaling and extracellular matrix synthesis in chondrocytes (76). As for osteoporosis, Mo et al. (77) revealed that m6A-associated single nucleotide polymorphisms (SNPs) can affect bone mineral density (BMI). Their GWAS result showed that 138, 125, and 993 m6A-SNPs were associated with varying risk of breast cancer. For instance, presence of rs1121980) in the FTO gene is associated with a high risk of breast cancer. Wu et al. (84) revealed that overexpression of METTL3, METTL14, FTO, and ALKBH5, and under-expression of WTAP was closely related with luminal type breast cancer, while the expression level of FTO was significantly decreased in human epidermal growth factor receptor 2 (HER2) positive breast cancer. Xiao et al. (85) illustrated that detection of m6A combined with METTL14 and FTO expression in peripheral blood can diagnose breast cancer with a specificity of 97.4%

Third, recent studies have found that the tumor microenvironment can induce the dysregulation of m6A regulators (86–88). For example, hypoxia can alter the level/activity of METTL14, ALKBH5, and YTHDF3, leading to decreased m6A modification in the target transcripts in breast cancer cells (86). Stress due to metabolic starvation can elevate the expression of FTO through the autophagy and NF-kB pathways (87). Inflammatory stimuli can induce YTHDF2 expression in hematopoietic stem cell (88). The bone microenvironment including mesenchymal stem cells (MSCs), hypoxia, acidic condition, chemokines and immune cells, is regarded as fertile soil for osteosarcoma (89, 90). Given this, the elucidation of m6A signatures and the bone microenvironment in osteosarcoma deserves further study.

#### DISCUSSION

### Clinical Implications of m6A for Osteosarcoma

Considering that the dysregulation of m6A modification has been linked to the initiation, metastasis, drug resistance, and other processes of osteosarcoma, m6A may bring new breakthroughs in the diagnosis and treatment of osteosarcoma.

On the one hand, m6A regulatory enzymes could be novel potential biomarkers for the early diagnosis and prognosis of osteosarcoma. High m6A methylation levels and dysregulated m6A enzymes always occur in patients with osteosarcoma. Based on two large-scale cohorts, HNRNPA2B1, HNRNPC, RBM15, YTHDF1, and YTHDC1 expression levels are upregulated in osteosarcoma tissues. Among them, HNRNPA2B1 was suggested to be an independent prognostic risk factor in patients with osteosarcoma and predict poor survival rates (63). On the other hand, m6A may also serve as a novel therapeutic target in osteosarcoma. m6A modification is pivotal in almost all pathophysiological processes of osteosarcoma, including tumorigenesis, invasion, and metastasis (64, 68, 69, 71). The small molecule inhibitor of m6A regulators has been regarded as a kind of potential anti-cancer agent (91, 92). Currently, several FTO and ALKBH5 inhibitors have been successfully identified, including N-oxalylglycine, entacapone, and meclofenamic acid (MA) (93–95). Furthermore, in vitro experiments have shown that these inhibitors can inhibit tumor growth (96). Encouragingly, entacapone and MA are already in the early phases of clinical trials for patients with late-stage cancer (97). Additionally, m6A also plays a key role in the resistance to chemotherapy of osteosarcoma. METTL3 and ALKBH5 expression levels are upregulated in doxorubicin-resistant osteosarcoma cells, while METTL14 expression is downregulated...
(70). YTHDF2 knockdown can significantly increase the expression of TRIM7 and cause resistance to doxorubicin and methotrexate treatment (69). Therefore, targeting dysregulated m6A enzymes represents an attractive strategy for cancer therapy. It can not only directly inhibit tumor growth but also sensitize cancer cells to anti-cancer agents.

Immunotherapy has emerged as a promising treatment modality that largely expands the therapeutic regimen for cancer (98). Bone is characterized as a highly specialized immune environment, and some immune-related factors are frequently dysregulated in osteosarcoma (99). Overall, the expression level of tumor-associated macrophages is reduced in metastatic osteosarcoma, while tumor-infiltrating lymphocytes appear to be associated with enhanced metastases in osteosarcoma (100). Programmed death ligand-1, one of the most effective immune checkpoint modulators, is expressed in approximately 25% of primary osteosarcoma tumors and is associated with poor prognosis (100, 101). However, immune checkpoint inhibitors are less effective in treating osteosarcoma (102). In the SARC028 trial, only 1 of the 22 patients with osteosarcoma, who received pembrolizumab (an anti-programmed death 1 (PD-1) antibody) showed a good response (103). In the PEMBROSARC study, 17 patients with advanced osteosarcoma received a combination of pembrolizumab and cyclophosphamide, and only 2 patients had significant clinical benefits (104). Interestingly, more studies have indicated that m6A regulators play an essential role in host immunity and may contribute to anticancer immunotherapy (105, 106). For instance, Han et al. (105) found that the m6A reader, YTHDF1, can promote the translation of mRNAs encoding lysosomal proteases. Downregulation of YTHDF1 results in the reduction of antigen cross-presentation and alleviation of the cytotoxic lymphocyte response against tumor antigens in dendritic cells, thereby enhancing the effectiveness of the PD-1 blockade therapy. Similarly, the m6A eraser, ALKBH5, can regulate the lactate content, tumor-infiltrating regulatory T cells, and myeloid-derived suppressor cell accumulation in the tumor microenvironment. In mouse melanoma, depleting ALKBH5 improved the efficacy of anti–PD-1 therapy and had survival benefits (106). In view of the promising effect of immunotherapy in cancers and the close association of m6A modification with immune response, there are reasons to believe that combining anticancer immunotherapy with m6A signatures may pave a way to improve the therapeutic effects of osteosarcoma.

Conclusions and Future Perspective

M6A modification has emerged as an indispensable factor that accounts for tumor initiation and progression in osteosarcoma. The function of m6A modification is just like that of a “double-edged sword”, by which it can either accelerate or inhibit the progression of osteosarcoma via different modes. Undoubtedly, the advent of m6A regulation has provided new insight into the molecular mechanism of osteosarcoma and will potentially help develop new more effective therapies.

However, a full understanding of the mechanism underlying m6A modification is still in its infancy, several knowledge gaps remain. First, existing studies on m6A in osteosarcoma mainly focused on writers; the dysregulation of m6A erasers and readers in osteosarcoma require further study. Second, although m6A is considered a potential biomarker for the diagnosis and prognosis of osteosarcoma, only few studies have yet elucidated the relationship between m6A-related factors and the molecular epidemiology as well as clinicopathology of osteosarcoma. Third, the clinical guidance of sequencing data of small osteosarcoma samples is limited due to the high genomic heterogeneity of this disease. Therefore, a large sample of sequencing database for m6A-related factors and osteosarcoma is warranted. Fourth, researchers have noted the potential of m6A as a therapeutic target for osteosarcoma, but few studies have focused on the application of potent and specific drugs that target m6A enzymes in osteosarcoma. In addition, compared with other cancer, osteosarcoma has its own biological and clinical features, such as the close connection with bone microenvironment and poor immunotherapy effect. Hence, combining m6A factors with tumor microenvironment and anticancer immunotherapy in osteosarcoma must be explored.

AUTHOR CONTRIBUTIONS

YZ, YYW, and LY conceived and designed the research. YZ, YYW, and ST searched the literature and analyzed the data. YZ and YYW wrote the manuscript and created the figures. YYW, PL, MS, and BH reviewed and made significant revisions to the manuscript. YZ, YYW, and LY contributed equally to this work as the first authors. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by the Nature Science Foundation of Zhejiang Province (LQ19H060002, LQ19H160041 and LY18H060004) and the Medical and Health Science and Technology Project of Zhejiang Province (2020KY143).

REFERENCES

1. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma Incidence and Survival Rates From 1973 to 2004: Data From the Surveillance, Epidemiology, and End Results Program. Cancer (2009) 115:1531–43. doi: 10.1002/cncr.24121
2. Ward E, Desantis C, Robbins A, Kohler B, Jamal A. Childhood and Adolescent Cancer Statistics. CA Cancer J Clin (2014) 64:83–103. doi: 10.3322/caac.21219
3. Whelan JS, Davis LE. Osteosarcoma, Chondrosarcoma, and Chordoma. J Clin Oncol (2018) 36:188–93. doi: 10.1200/JCO.2017.75.1743
4. Kansara M, Teng MW, Smyth MJ, Thomas DM. Translational Biology of Osteosarcoma. Nat Rev Cancer (2014) 14:722–35. doi: 10.1038/nrc3838
5. Link MP, Goorin AM, Misro AW, Green AA, Pratt CB, Belasco JB, et al. The Effect of Adjuvant Chemotherapy on Relapse-Free Survival in Patients With Osteosarcoma of the Extremity. N Engl J Med (1986) 314:1600–6. doi: 10.1056/NEJM198606193142502
6. Meyers PA, Healey JH, Chou AJ, Wexler LH, Merola PR, Morris CD, et al. Addition of Pamidronate to Chemotherapy for the Treatment of Osteolytic Metastases. Cancer (2011) 117:1736–44. doi: 10.1002/cncr.25744

7. Miller BJ, Cramp P, Lynch CF, Buckwalter JA. Risk Factors for Metastatic Disease At Presentation With Osteosarcoma: An Analysis of the SEER Database. J Bone Joint Surg Am (2013) 95:e89. doi: 10.2106/JBJS.L.01189

8. Mirabello L, Shi L, Ye Y, Shi H, Zeng L, Tiwary S, et al. Ythdf3 Induces the Expression of SOX4 mRNA Inhibits Tumor Metastasis in Colorectal Cancer. Cancer Discovery (2020) 10:911. doi: 10.3389/fendo.2019.00911

9. Savage SA, Mirabello L. Bone Cancer: Is the Osteosarcoma Genome Targetable? Curr Opin Genet Dev (2017) 42:169–76. doi: 10.1016/j.gde.2018.04.002

10. Smida J, Xu H, Zhang Y, Baumhoer D, Bibi S, Kovac M, et al. Genome-Wide Analysis of Somatic Copy Number Alterations and Chromosomal Breakages in Osteosarcoma. Int J Cancer (2017) 141:816–28. doi: 10.1002/ijc.30778

11. Perez MF, Lehner B. Intergenerational and Transgenerational Epigenetic Inheritance in Animals. Nat Cell Biol (2019) 21:143–51. doi: 10.1038/s41556-018-0124-9

12. Frye M, Jaffrey SR, Pan T, Rechavi G, Suzuki T. RNA Modifications: What Have We Learned and Where Are We Headed? Nat Rev Genet (2016) 17:365–72. doi: 10.1038/nrg.2016.47

13. Roundtree IA, Evans ME, Pan T, He C. Dynamic RNA Modifications in Gene Expression Regulation. Cell (2017) 169:1187–200. doi: 10.1016/j.cell.2017.05.045

14. Desrosiers R, Friderici K, Rottmann F. Identification of Methylated Nucleosides in Messenger RNA From Novikoff Hepatoma Cells. Proc Natl Acad Sci USA (1974) 71:3971–5. doi: 10.1073/pnas.71.10.3971

15. Goh YT, Koh CWQ, Sim DY, Roca X, Goh WSS. METTL4 Catalyzes m6Am Methylation in U2 snRNA to Regulate pre-mRNA Splicing. Nucleic Acids Res (2020) 48:9250–61. doi: 10.1093/nar/gkaa848

16. Chen RX, Chen X, Xia LP, Zhang JX, Pan ZZ, Ma XD, et al. N(6)-Methyladenosine Modification of circNSUN2 Facilitates Cytosplasmic Export and Stabilizes HMGa2 to Promote Colorectal Liver Metastasis. Nat Commun (2019) 10:4695. doi: 10.1038/s41467-019-12651-2

17. Chang G, Shi L, Ye Y, Shi H, Zeng L, Tiwary S, et al. Yhdh3 induces the Translation of M(6a)-Enriched Gene Transcripts to Promote Breast Cancer Brain Metastasis. Cancer Cell (2020) 38:857–71.e857. doi: 10.1016/j.ccell.2020.10.004

18. Dixit D, Prager BC, Gimple RC, Poh HK, Wang Y, Wu Q, et al. The RNA m6a Reader YTHDF2 Maintains Oncogene Expression and is a Targetable Dependency in Glioblastoma Stem Cells. Cancer Discovery (2020) 11:480–99. doi: 10.1158/2159-8290.CD-19-0225

19. Chen X, Xu M, Xu X, Zeng K, Liu X, Pan B, et al. METTL14-Mediated N6-methyladenosine Methylation in mRNA With A Dynamic and Reversible Epigenetic Regulation of AGO2 mRNA Stability. Nat Cell Biol (2019) 21:1391–1403. doi: 10.1038/s41556-018-0045-z

20. Dominissini D, Moshitch-Moshkovitz S, Schwartz S, Salmon-Divon M, Ungar L, Olsenberg S, et al. Topology of the Human and Mouse M6a RNA Methyomers Revealed by M6a-Seq. Nature (2012) 485:201–6. doi: 10.1038/nature11112

21. Meyer KD, Saletore Y, Zumbo P, Elemento O, Mason CE, Jaffrey SR. Comprehensive Analysis of mRNA Methylation Reveals Enrichment in 3′ UTRs and Near Stop Codons. Cell (2012) 149:1635–46. doi: 10.1016/j.cell.2012.05.003

22. Huang H, Weng H, Chen J. M(6)a Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer. Cancer Cell (2020) 37:270–88. doi: 10.1016/j.ccell.2020.02.004

23. Chen X, Hua W, Huang X, Chen Y, Zhang J, Li G. Regulatory Role of RNA N(6)-Methyladenosine Modification in Bone Biology and Osteoporosis. Front Endocrinol (Lausanne) (2019) 10. doi: 10.3389/fendo.2019.00911

24. Wu R, Jiang D, Wang Y, Wang X, N(6)-Methyladenosine (M(6)a) Methylation in mRNA With A Dynamic and Reversible Epigenetic Modification. Mol Biotechnol (2016) 58:450–9. doi: 10.1007/s12033-016-9497-9

25. Zucca S, Ries RJ, Jaffrey SR. Reading, Writing and Erasing mRNA Methylation. Nat Rev Mol Cell Biol (2019) 20:668–24. doi: 10.1038/s41580-019-0168-5

26. Wang X, Huang J, Zou T, Yin P, Human M(6)a Writers: Two Subunits, 2 Roles. RNA Biol (2017) 14:300–4. doi: 10.1080/15476286.2017.1282025
48. Kan L, Grozovik AV, Vedanyagam J, Patil DP, Pang N, Lim KS, et al. The M(6)a Pathway Facilitates Sex Determination in Drosophila. *Nat Commun* (2017) 8:15737. doi: 10.1038/ncomms15737

49. Roundtree IA, Luo GZ, Zhang Z, Wang X, Zhou T, Cui Y, et al. YTHDC1 Mediates Nuclear Export of N(6)-methyladenosine Methylated Mrnas. *Elife* (2017) 6:e33111. doi: 10.7554/elife.33111

50. Wang X, Lu Z, Gomez A, Hon GC, Yue Y, Han D, et al. N6-Methyladenosine-Dependent Regulation of Messenger RNA Stability. *Nature* (2014) 505:117–20. doi: 10.1038/nature12730

51. Weng H, Huang H, Wu H, Qin X, Zhao BS, Dong L, et al. Mettl14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis Via mRNA M(6)a Modification. *Cell Stem Cell* (2018) 22:191–205.e199. doi: 10.1016/j.stem.2017.11.016

52. Gao Y, Vasic R, Song Y, Teng R, Liu C, Gbyli R, et al. Mettl3 Modulation of Endogenous Double-Stranded RNAs and Deleterious Innate Immune Responses During Hematopoietic Development. *Immunity* (2020) 52:1007–21. doi: 10.1016/j.immuni.2020.05.003

53. Liu J, Harada BT, He C. Regulation of Gene Expression by N(6)-methyladenosine in Cancer. *Trends Cell Biol* (2019) 29:487–99. doi: 10.1016/j.tcb.2019.02.008

54. Cui X, Wang Z, Li J, Zhu J, Ren Z, Zhang D, et al. Cross Talk Between RNA N6-Methyladenosine Methyltransferase-Like 3 and miR-186 Regulates Hepatoblastoma Progression Through Wnt/β-Catenin Signalling Pathway. *Cell Prolif* (2020) 53:e12399. doi: 10.1111/cpi.12399

55. Kim JM, Lin C, Stavrak S, Greenblatt MB, Shim JH. Osteoblast-Osteoclast Communication and Bone Homeostasis. *Cells* (2020) 9:2073. doi: 10.3390/cells9092073

56. Song W, Xie J, Li J, Bao C, Xiao Y. The Emerging Roles of Long Noncoding RNAs in Bone Homeostasis and Their Potential Application in Bone-Related Diseases. *DNA Cell Biol* (2020) 39:926–37. doi: 10.1089/dna.2020.5391

57. Zhang Y, Gu X, Li D, Cai L, Xu Q, Mettl3 Regulates Osteoblast Differentiation and Inflammatory Response Via Smad Signaling and MAPK Signaling. *Int J Mol Sci* (2019) 21:199. doi: 10.3390/ijms21011999

58. Yan G, Yuan Y, He M, Gong R, Lei H, Zhou H, et al. M(6)a Methylation of Precursor-miR-320/RUNX2 Controls Osteogenic Potential of Bone Marrow-Derived Mesenchymal Stem Cells. *Mol Ther Nucleic Acids* (2019) 19:421–36. doi: 10.1016/j.omtn.2019.12.001

59. Li D, Cai L, Meng R, Feng Z, Xu Q, Mettl3 Modulates Osteoclast Function and Differentiation by Controlling RNA Stability and Nuclear Export. *Int J Mol Sci* (2020) 21:1660. doi: 10.3390/ijms21051660

60. Sun Z, Wang H, Wang Y, Yuan G, Yu X, Jiang H, et al. MiR-103-3p Targets the M(6)A MicroRNA Methyltransferase METTL14 to Inhibit Osteoblastic Bone Formation. *Aging Cell* (2020) 19:1372–80. doi: 10.1111/ace.13728

61. Li Y, Yang F, Gao M, Gong R, Ji M, Liu T, et al. MiR-143-3p Regulates the Switch Between Adipogenic and Osteogenic Differentiation of BMSCs by Targeting Fto. *Mol Ther Nucleic Acids* (2019) 17:590–600. doi: 10.1016/j.omtn.2019.06.023

62. Gianferante DM, Mirabelli L, Savage SA. Germline and Somatic Genetics of Osteosarcoma - Connecting Aetiology, Biology and Therapy. *Trends Cell Biol* (2019) 9:2073. doi: 10.3390/tcb.2019.05.008

63. Zeng X, Ban Z, Cao J, Zhang W, Chu T, Lei D, et al. Association of FTO Timepoint-Associated SNPs as Potential Functional Variants for Bone Mineral Density. *Osteoporos Int* (2019) 28:2929–39. doi: 10.1007/s00198-018-4573-y

64. Wu Y, Xie L, Wang M, Xiong Q, Guo Y, Liang Y, et al. Mettl3-mediated M(6)a RNA Methylation Regulates the Fate of Bone Marrow Mesenchymal Stem Cells and Osteoporosis. *Nat Commun* (2018) 9:4772. doi: 10.1038/s41467-018-06898-4

65. Tang B, Yang Y, Kang M, Wang Y, Wang Y, Bi Y, et al. M(6)A Demethylase ALKBH5 Inhibits Pancreatic Cancer Tumorigenesis by Decreasing Wnt-1 RNA Methylation and Mediating Wnt Signaling. *Mol Cancer* (2020) 19:12. doi: 10.1088/s41493-019-1128-6

66. Guo X, Li K, Jiang W, Hu Y, Xiao W, Huang Y, et al. RNA Demethylase ALKBH5 Prevents Pancreatic Cancer Progression by Posttranscriptional Activation of PER1 in an M(6)-A-YTHDF2-dependent Manner. *Mol Cancer* (2020) 19:91. doi: 10.1186/s12943-020-01158-w

67. Paris J, Morgan M, Campos J, Spencer GJ, Shimakova A, Ivanova I, et al. Targeting the RNA M(6)A Reader Ythdf2 Selectively Compromises Cancer Stem Cells in Acute Myeloid Leukemia. *Cell Stem Cell* (2019) 25:137–48. doi: 10.1016/j.stem.2019.03.021

68. Lia Y, Li H, Liu F, Gao LB, Han R, Chen C, et al. Heterogeneous Nuclear Ribonucleoprotein A2/B1 is a Negative Regulator of Human Breast Cancer Metastasis by Maintaining the Balance of Multiple Genes and Pathways. *ElifeMedicine* (2020) 51:102583. doi: 10.7554/eLife.2019.11.044

69. Zeng X, Ban Z, Cao J, Zhang W, Chu T, Lei D, et al. Association of FTO Timepoint Mutations With Risk and Survival of Breast Cancer in a Chinese Population. *Dis Markers* (2015) 2015:101032. doi: 10.1155/2015/101032

70. Wu L, Wu D, Ning J, Liu Z, Zhang D, Changes of N6-methyladenosine Modulators Promote Breast Cancer Progression. *BMCMed Cancer* (2019) 19:326. doi: 10.1186/s12885-019-2128-6

71. Xiong F, Han X, Zhang R, Wu G. Upregulated N6-Methyladenosine RNA in Peripheral Blood Potential Diagnostic Biomarker for Breast Cancer. *Cancer Treat Res* (2021) 53:399–408. doi: 10.4143/crt.2020.870

72. Panneerdsso S, Eedunuri VK, Yadav P, Timilsina S, Rajamanickam S, Viswanadhapalli S, et al. Cross-Talk Among Writers, Readers, and Erasers
of M(6)a Regulates Cancer Growth and Progression. Sci Adv (2018) 4: eaar8263. doi: 10.1126/sciadv.eaar8263
87. Yang S, Wei J, Cui YH, Park G, Shah P, Deng Y, et al. M(6)a mRNA Demethylase FTO Regulates Melanoma Tumorigenicity and Response to anti-PD-1 Blockade. Nat Commun (2019) 10:2782. doi: 10.1038/s41467-019-10669-0
88. Mapperley C, Van De Lagenaat LN, Lawson H, Tajosanis A, Paris J, Campos J, et al. The mRNA m6A Reader YTHDF2 Suppresses Proinflammatory Pathways and Sustains Hematopoietic Stem Cell Function. J Exp Med (2021) 218:e20200829. doi: 10.1084/jem.20200829
89. Yang C, Tian Y, Zhao F, Chen Z, Su P, Li Y, et al. Bone Microenvironment and Osteosarcoma Metastasis. Int J Mol Sci (2020) 21:6985. doi: 10.3390/ijms21196985
90. Zhou Y, Yang D, Yang Q, Lv X, Huang W, Zhou Z, et al. Single-Cell RNA Landscape of Intratumoral Heterogeneity and Immunosuppressive Microenvironment in Advanced Osteosarcoma. Nat Commun (2020) 11:6322. doi: 10.1038/s41467-020-20059-6
91. Su R, Dong L, Li Y, Gao M, Han L, Wunderlich M, et al. Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. Cancer Cell (2020) 38:79–96. doi: 10.1016/j.ccell.2020.04.017
92. Huang Y, Su R, Sheng Y, Dong L, Dong Z, Xu H, et al. Small-Molecule Targeting of Oncogenic Fto Demethylase in Acute Myeloid Leukemia. Cancer Cell (2019) 35:677–91. doi: 10.1016/j.ccell.2019.03.006
93. Peng S, Xiao W, Ju D, Sun B, Hou N, Liu Q, et al. Identification of Entacapone as a Chemical Inhibitor of FTO Mediating Metabolic Regulation Through FOXO1. Sci Transl Med (2019) 11:eaua7116. doi: 10.1126/scitranslmed.aau7116
94. Huang Y, Yan J, Li Q, Li J, Gong S, Zhou H, et al. Meclofenamic Acid Selectively Inhibits FTO Demethylation of m6A Over ALKBH5. Nucleic Acids Res (2015) 43:373–84. doi: 10.1093/nar/gku1276
95. Islam MS, Leissing TM, Chowdhury R, Hopkins RJ, Schofield CJ. 2-Oxoglutarate-Dependent Oxoglycogenes. Annu Rev Biochem (2018) 87:585–620. doi: 10.1146/annurev-biochem-061516-044724
96. Niu Y, Wan A, Lin Z, Lu X, Wan G. N (6)-Methyladenosine Modification: A Novel Pharmacological Target for Anti-Cancer Drug Development. Acta Pharm Sin B (2018) 8:833–43. doi: 10.1016/j.apsb.2018.06.001
97. Li B, Jiang J, Assaraf YG, Xiao H, Chen ZS, Huang C. Surmounting Cancer Drug Resistance: New Insights From the Perspective of N(6)-methyladenosine RNA Modification. Drug Resist Update (2020) 53:100720. doi: 10.1016/j.drup.2020.100720
98. Galluzzi L, Chan TA, Kroemer G, Wolchok JD, López-Soto A. The Hallmarks of Successful Anticancer Immunotherapy. Sci Transl Med (2018) 10:eaa7807. doi: 10.1126/scitranslmed.aat7807
99. Grabowski P. Physiology of Bone. Endocr Dev (2009) 16:32–48. doi: 10.1159/000233687
100. Li N, Kang Y, Wang L, Huff S, Tang R, Hui H, et al. ALKBH5 Regulates anti-PD-L1 Response by Modulating Lactate and Suppressive Immune Cell Accumulation in Tumor Microenvironment. J Exp Med (2020) 218:e20200829. doi: 10.1084/jem.20200829
Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.